Thursday November 26 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

3SBio

Shenyang Sunshine Pharmaceutical Company Limited (SUNSHINE) is an integrated biopharmaceutical company engaged in research/development, manufacture and marketing/sales of biopharmaceutical products in China. Our recombinant, or genetically engineered, protein-based products and product candidates are designed to address large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious disease. We began operations in 1993. Currently, our principal products are EPIAO®, TPIAO®, INTEFEN® and INLEUSIN®. SUNSHINE is now one of the largest biopharmaceutical companies in China in terms of market shares, growth and profitability. Manufacturing facilities Our clinical and commercial manufacturing operations are based in Shenyang, China, where our Chinese current Good Manufacturing Practice, or cGMP, certified, 3,000 square meters, and state-of-the-art facility resides. Our manufacturing facilities consist of on-site bulk manufacturing, formulation, fill, finishing and packaging activities for EPIAO, TPIAO, INTEFEN and INLEUSIN. With these facilities, we are able to produce our products and product candidates for both clinical and commercial purposes. We plan to expand our plant in Shenyang to increase our manufacturing capacity and take further advantage of our favorable cost structure.

The sales and marketing team We maintain a sales and marketing force in 18 provinces and major cities in China, including Beijing and Shanghai and Guangzhou. Our over 150 sales and marketing professionals market, and our network of approximately 80 distributors sell our principal products to healthcare providers including, based on our internal estimates, approximately 800 hospitals, clinics and dialysis centers. Our sales force in China benefits from over ten years of experience in marketing protein-based therapeutics. As a result of our history as a provider of protein therapeutics to the Chinese market, we believe our Shenyang Sunshine brand is widely recognized throughout the PRC for quality and reliability.

Research and development Our research and development team consisted of many research personnel and medical professionals, including two PhDs, two MDs and three holders of master’s degrees and many of whom have years of experience in the healthcare and biotechnology research fields, including experience working in research institutions and hospitals and in proceeding through the SFDA drug approval process.

Our product pipeline We focus our research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Our product pipeline, which we expect will be a key contributor to our future growth, consists of six product candidates in various stages of development. We employ a market-driven approach to our research and development efforts, and our team utilizes the latest molecular biology and biochemical techniques and technologies to develop promising product candidates. Our diversified product pipeline includes a number of next-generation protein-based therapeutics including NuPIAO, our second generation EPIAO product candidate; NuLeusin, our next-generation Inleusin product candidate; TPIAO for the treatment of ITP; a human papilloma virus, or HPV, vaccine for the prevention of cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases. We believe that each of these product candidates, if successfully developed and approved, would address significant market opportunities. For all of our programs, we conduct extensive preclinical and clinical trials in order to generate safety and efficacy data to support a filing for approval as required to the SFDA.


Contact Details:
No. 3 A1, Road 10
Shenyang
China
Tel:(86-24) 2581-1820
Fax:
Email:
WWW:

bbs.3sbio.com/en/Index.aspx




Press Releases on 3SBio:

BioPortfolio Logo
3SBio Inc. Announces Unaudited Third Quarter 2009 Results 12th November, 2009 3SBio Inc.
SHENYANG, China, Nov. 12 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching
3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009 27th October, 2009 3SBio Inc.
SHENYANG, China, Oct. 27 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching
3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009 23rd July, 2009 3SBio Inc.
SHENYANG, China, July 23 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing
3SBio Inc. Announces Unaudited First Quarter 2009 Results 19th May, 2009 3SBio Inc.
SHENYANG, China, May 19 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching,
3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor 5th May, 2009 3SBio Inc.
SHENYANG, China, May 5 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching,

BioNews Results for 3SBio:

3SBio Inc. Announces Unaudited Third Quarter 2009 Results
KOTA Territory News:  Nov 14 2009 11:04PM Matching: 3sbio
3SBio Inc. Announces Unaudited Third Quarter 2009 Results
Pharma Live:  Nov 14 2009 10:19PM Matching: 3sbio
3SBio Inc. Announces Unaudited Third Quarter 2009 Results
KSLA:  Nov 14 2009 7:28AM Matching: 3sbio
3SBio Inc. Announces Unaudited Third Quarter 2009 Results
Genetic Engineering News:  Nov 13 2009 7:07AM Matching: 3sbio
3SBio Inc. Announces Unaudited Third Quarter 2009 Results
RBC Dain Rauscher:  Nov 13 2009 9:43AM Matching: 3sbio
Promote your company here: BioNewsCast - Press Release Distribution

View more 3SBio news.

3SBio (SSRX) Financial information Links from Barchart

SSRX Quote from from Barchart.com
SSRX Chart from from Barchart.com
SSRX Profile from from Barchart.com
SSRX Opinion from from Barchart.com

View more 3SBio finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 286 times since April 2007, the link to the organisation's website has been followed 50 times

Recent Search Terms used to find this page: email of 3sbio | .

Search for more companies in Shenyang

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for 3SBio

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.